Conditions: Liver Diseases Hepatic Insufficiency
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 16
Healthy volunteers: yes

Brief summary:
The main purpose of this study is to measure how much of the study drug called baricitinib gets into the blood stream and how long it takes the body to get rid of it. Healthy participants and those with liver disease may enroll. The study will last about 7 days for each participant, not including screening.

Detailed description:

Arms:
arm 1: Group 1: 4 milligrams (mg) baricitinib administered once, orally, to participants with normal hepatic function. arm 2: Group 2: 4 mg baricitinib administered once, orally, to participants with moderate hepatic impairment. arm 3: Group 3: 4 mg baricitinib administered once, orally, to participants with mild hepatic impairment. Enrollment is contingent on data from Groups 1 and 2.

Interventions: intervention 1: Baricitinib
Intervention descriptions: intervention 1: Administered orally

Protocol document: